SCHEMBL3496906

SCHEMBL3496906

CCOC([C]=O)OCCN

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1682635 0.83
SCHEMBL9660243 0.78 CYP3A4 (0.33) THRB
SCHEMBL5571941 0.78 THRB (0.31) THRB
SCHEMBL27584519 0.74
SCHEMBL1792660 0.72
SCHEMBL3496904 0.70 LMNA (0.35) THRB
SCHEMBL2867592 0.68 CYP3A4 (0.36)
SCHEMBL3012936 0.67
SCHEMBL3393450 0.67
SCHEMBL27589425 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230050846-A1 TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) 2023-02-16 US disclosed
WO-2021123300-A1 TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS LIFESEARCH (FR) 2021-06-24 WO disclosed
US-20100112619-A1 LIGAND-CONTAINING MICELLES AND USES THEREOF GRAHAM RONALD J 2010-05-06 US disclosed
EP-1537230-A4 FLUORESCENT ENZYME ASSAY METHODS AND COMPOSITIONS APPLERA CORP (US) 2008-06-18 EP disclosed
EP-1687635-A2 LIGAND-CONTAINING MICELLES AND USES THEREOF Applera Corporation (US) 2006-08-09 EP disclosed
CN-1697880-A Fluorogenic enzyme assay methods and compositions APPLERA CORP (US) 2005-11-16 CN disclosed
US-20050244891-A1 Ligand-containing micelles and uses thereof APPLERA CORPORATION (US) 2005-11-03 US disclosed
WO-2005054495-A2 LIGAND-CONTAINING MICELLES AND USES THEREOF APPLERA CORPORATION (US) 2005-06-16 WO disclosed
EP-1537230-A1 FLUORESCENT ENZYME ASSAY METHODS AND COMPOSITIONS Applera Corporation (US) 2005-06-08 EP disclosed
US-20040146959-A1 Fluorescent enzyme assay methods and compositions APPLIED BIOSYSTEMS, LLC 2004-07-29 US disclosed
WO-2004022773-A1 FLUORESCENT ENZYME ASSAY METHODS AND COMPOSITIONS APPLERA CORPORATION (US) 2004-03-18 WO disclosed
US-5643878-A TREATMENT OF RETROVIRAL DISEASES LIKE AIDS CIBA-GEIGY CORPORATION (US) 1997-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230050846-A1 TREATMENT OF HEPATIC AND CARDIOVASCULAR DISORDERS FABP1, FABP3, PCSK9 MEN1 2676/4885CYP1A2 943/4885KMT2A 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.